These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 28288682)

  • 1. Low disease activity for up to 3 years after adalimumab discontinuation in patients with early rheumatoid arthritis: 2-year results of the HOPEFUL-3 Study.
    Tanaka Y; Yamanaka H; Ishiguro N; Miyasaka N; Kawana K; Kimura J; Agata N; Takeuchi T
    Arthritis Res Ther; 2017 Mar; 19(1):56. PubMed ID: 28288682
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adalimumab discontinuation in patients with early rheumatoid arthritis who were initially treated with methotrexate alone or in combination with adalimumab: 1 year outcomes of the HOPEFUL-2 study.
    Tanaka Y; Yamanaka H; Ishiguro N; Miyasaka N; Kawana K; Hiramatsu K; Takeuchi T
    RMD Open; 2016; 2(1):e000189. PubMed ID: 26925252
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naive patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study.
    Detert J; Bastian H; Listing J; Weiß A; Wassenberg S; Liebhaber A; Rockwitz K; Alten R; Krüger K; Rau R; Simon C; Gremmelsbacher E; Braun T; Marsmann B; Höhne-Zimmer V; Egerer K; Buttgereit F; Burmester GR
    Ann Rheum Dis; 2013 Jun; 72(6):844-50. PubMed ID: 22739990
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study.
    Kavanaugh A; Fleischmann RM; Emery P; Kupper H; Redden L; Guerette B; Santra S; Smolen JS
    Ann Rheum Dis; 2013 Jan; 72(1):64-71. PubMed ID: 22562973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adalimumab, a human anti-TNF monoclonal antibody, outcome study for the prevention of joint damage in Japanese patients with early rheumatoid arthritis: the HOPEFUL 1 study.
    Takeuchi T; Yamanaka H; Ishiguro N; Miyasaka N; Mukai M; Matsubara T; Uchida S; Akama H; Kupper H; Arora V; Tanaka Y
    Ann Rheum Dis; 2014 Mar; 73(3):536-43. PubMed ID: 23316080
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of methotrexate dose on efficacy of adalimumab in Japanese patients with rheumatoid arthritis: Results from registered data analyses.
    Nakashima Y; Miyahara H; Kondo M; Fukuda T; Harada H; Haraguchi A; Inoue Y; Ishinishi T; Maekawa M; Maeyama A; Nakashima M; Shono E; Suematsu E; Shimauchi T; Tsuru T; Tsukamoto H; Yoshizawa S; Yoshizawa S; Iwamoto Y
    Mod Rheumatol; 2017 Jan; 27(1):15-21. PubMed ID: 27142240
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discontinuation of adalimumab treatment in rheumatoid arthritis patients after achieving low disease activity.
    Harigai M; Takeuchi T; Tanaka Y; Matsubara T; Yamanaka H; Miyasaka N
    Mod Rheumatol; 2012 Nov; 22(6):814-22. PubMed ID: 22270346
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness, safety, and methotrexate dose-tapering pattern over two years of treatment with adalimumab and ≥12 mg/week methotrexate for early rheumatoid arthritis: Results of the HAWK postmarketing surveillance study in Japan.
    Tanaka Y; Mimori T; Yamanaka H; Sunaga N; Morita K; Kimura J; Takeuchi T
    Mod Rheumatol; 2020 May; 30(3):424-433. PubMed ID: 31267801
    [No Abstract]   [Full Text] [Related]  

  • 9. Disease activity, physical function, and radiographic progression after longterm therapy with adalimumab plus methotrexate: 5-year results of PREMIER.
    van der Heijde D; Breedveld FC; Kavanaugh A; Keystone EC; Landewé R; Patra K; Pangan AL
    J Rheumatol; 2010 Nov; 37(11):2237-46. PubMed ID: 20889601
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study.
    Smolen JS; Burmester GR; Combe B; Curtis JR; Hall S; Haraoui B; van Vollenhoven R; Cioffi C; Ecoffet C; Gervitz L; Ionescu L; Peterson L; Fleischmann R
    Lancet; 2016 Dec; 388(10061):2763-2774. PubMed ID: 27863807
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment.
    Breedveld FC; Weisman MH; Kavanaugh AF; Cohen SB; Pavelka K; van Vollenhoven R; Sharp J; Perez JL; Spencer-Green GT
    Arthritis Rheum; 2006 Jan; 54(1):26-37. PubMed ID: 16385520
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 5-year remission rate after the discontinuation of adalimumab in patients with rheumatoid arthritis: Long-term follow-up results of the HONOR study.
    Yamaguchi A; Hirata S; Kubo S; Fukuyo S; Hanami K; Nakano K; Nakayamada S; Saito K; Tanaka Y
    Mod Rheumatol; 2020 Sep; 30(5):799-806. PubMed ID: 31814496
    [No Abstract]   [Full Text] [Related]  

  • 13. Final 10-year effectiveness and safety results from study DE020: adalimumab treatment in patients with rheumatoid arthritis and an inadequate response to standard therapy.
    Furst DE; Kavanaugh A; Florentinus S; Kupper H; Karunaratne M; Birbara CA
    Rheumatology (Oxford); 2015 Dec; 54(12):2188-97. PubMed ID: 26199453
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Effect of Reduced or Withdrawn Etanercept-methotrexate Therapy on Patient-reported Outcomes in Patients with Early Rheumatoid Arthritis.
    Wiland P; Dudler J; Veale D; Tahir H; Pedersen R; Bukowski J; Vlahos B; Williams T; Gaylord S; Kotak S
    J Rheumatol; 2016 Jul; 43(7):1268-77. PubMed ID: 27252426
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Time lag between the initiation of adalimumab after methotrexate correlates with the efficacy of adalimumab in rheumatoid arthritis patients.
    Kimura N; Suzuki K; Takeuchi T
    Mod Rheumatol; 2016 Sep; 26(5):676-80. PubMed ID: 26708943
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recovery of clinical but not radiographic outcomes by the delayed addition of adalimumab to methotrexate-treated Japanese patients with early rheumatoid arthritis: 52-week results of the HOPEFUL-1 trial.
    Yamanaka H; Ishiguro N; Takeuchi T; Miyasaka N; Mukai M; Matsubara T; Uchida S; Akama H; Kupper H; Arora V; Tanaka Y
    Rheumatology (Oxford); 2014 May; 53(5):904-13. PubMed ID: 24441150
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The rate of decrease in the disease activity of rheumatoid arthritis during treatment with adalimumab depends on the dose of methotrexate.
    Oh K; Ito S; Unno M; Kobayashi D; Azuma C; Abe A; Otani H; Ishikawa H; Nakazono K; Narita I; Murasawa A
    Intern Med; 2015; 54(9):1035-41. PubMed ID: 25948343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study.
    Tanaka Y; Hirata S; Kubo S; Fukuyo S; Hanami K; Sawamukai N; Nakano K; Nakayamada S; Yamaoka K; Sawamura F; Saito K
    Ann Rheum Dis; 2015 Feb; 74(2):389-95. PubMed ID: 24288014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Methotrexate Dosage Reduction Upon Adalimumab Initiation: Clinical and Ultrasonographic Outcomes from the Randomized Noninferiority MUSICA Trial.
    Kaeley GS; Evangelisto AM; Nishio MJ; Goss SL; Liu S; Kalabic J; Kupper H
    J Rheumatol; 2016 Aug; 43(8):1480-9. PubMed ID: 27307526
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An Analysis of the Biological Disease-modifying Antirheumatic Drug-free Condition of Adalimumab-treated Rheumatoid Arthritis Patients.
    Ito S; Kobayashi D; Hasegawa E; Takai C; Nemoto T; Lee H; Abe A; Otani H; Ishikawa H; Murasawa A; Narita I; Nakazono K
    Intern Med; 2019 Feb; 58(4):511-519. PubMed ID: 30210123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.